Francesca Zappacosta

GSK1120212 (JTP-74057) Is an Inhibitor of MEK Activity and Activation with Favorable Pharmacokinetic Properties for Sustained <i>In Vivo</i> Pathway Inhibition

Aidan G. Gilmartin, Maureen R. Bleam, Arthur Groy et al. · Clinical Cancer Research · 2011 · 590 citations · Full text

Anti-tumor Activity of the Type I PRMT Inhibitor, GSK3368715, Synergizes with PRMT5 Inhibition through MTAP Loss

Andrew Fedoriw, Satyajit Rajapurkar, Shane W. O’Brien et al. · Cancer Cell · 2019 · 333 citations · Full text

Cancer Research, Mtap Loss, Medicine +10

Redox Regulation of Cell Signaling by Selenocysteine in Mammalian Thioredoxin Reductases

Qi-An Sun, Yalin Wu, Francesca Zappacosta et al. · Journal of Biological Chemistry · 1999 · 325 citations · Full text

Redox Regulation, Lipid Peroxidation, Molecular Biology +17

Cell Cycle Regulation of Myosin-V by Calcium/Calmodulin-Dependent Protein Kinase II

Ryan L. Karcher, Joseph T. Roland, Francesca Zappacosta et al. · Science · 2001 · 152 citations

Single‐step purification and structural characterization of human interleukin‐6 produced in <i>Esherichia coli</i> From a T7 RNA polymerase expression vector

Rosaria Arcone, Piero Pucci, Francesca Zappacosta et al. · European Journal of Biochemistry · 1991 · 135 citations · Full text

Structural Characterization, Single‐step Purification, Immunology +20